Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?

Basit Öğe Kaydı
dc.authoridKaraboyun, Kubilay/0000-0002-1783-8075
dc.authoridSEBER, SELCUK/0000-0001-9081-2405
dc.authoridGULTURK, Ilkay/0000-0003-1998-3150
dc.authoridCavdar, Eyyup/0000-0001-5885-3047
dc.authoridiriagac, Yakup/0000-0001-7411-1705
dc.authoridcelebi, abdussamet/0000-0002-6922-1018
dc.authoridKAPAGAN, TANJU/0000-0001-9381-1934
dc.contributor.authorKaraboyun, Kubilay
dc.contributor.authorCavdar, Eyyup
dc.contributor.authorIriagac, Yakup
dc.contributor.authorCelebi, Abdussamet
dc.contributor.authorKapagan, Tanju
dc.contributor.authorGulturk, Ilkay
dc.contributor.authorDemir, Ozden
dc.date.accessioned2024-10-29T17:58:18Z
dc.date.available2024-10-29T17:58:18Z
dc.date.issued2023
dc.departmentTekirdağ Namık Kemal Üniversitesi
dc.description.abstractAimThe primary aim of this study was to compare tamoxifen versus aromatase inhibitors (AI) in terms of urinary incontinence (UI) in premenopausal female patients receiving adjuvant hormone therapy for breast cancer. A secondary aim was to investigate the prevalence and the affecting factors of UI.MethodsThis study was designed as a multicenter, cross-sectional that included consecutive premenopausal breast cancer patients <= 50 years of age receiving tamoxifen (with/without LHRHa) or AI (with LHRHa) for at least 6 months, between June 2021 and September 2022. Patients with urinary incontinence before hormone treatments and metastatic patients were excluded from the study. Turkish validation of The International Consultation on Incontinence Modular Questionnaire Urinary Incontinence Short Form (ICIQ UI-SF) was used to determine the UI. Using logistic regression methods, we analyzed potential predictive factors for UI.ResultsA total of 206 breast cancer patients were included in this study. A total of 120 (58.2%) patients were receiving tamoxifen plus LHRHa, 40 (19.4%) patients were receiving aromatase inhibitor plus LHRHa, and 46 (22.3%) patients were receiving tamoxifen only. In this study, the prevalence of urinary incontinence was found to be 35.9% (n:74). 41% of the patients receiving tamoxifen and 15.0% of those receiving aromatase inhibitors had complaints of urinary incontinence. There was a statistically significant difference between patients receiving tamoxifen or aromatase inhibitor in terms of urinary incontinence (p=0.001). In the univariate analysis established to predict UI, parity (>= 2 vs <2) (OR = 3.23, 95% CI: 1.62-6.46, p= 0.001), tamoxifen (vs AI) (OR = 3.97, 95% CI: 1.58-9.98, p= 0.003), age ( >= 40 vs. <40) (OR = 2.80, 95% CI: 1.37-5.71, p= 0.005), vaginal deliveries (>= 2 vs. <2) (OR = 3.28, 95% CI: 1.44-7.46, p= 0.005), hypertension (OR = 3.59, 95% CI: 1.43-9.02, p= 0.007), diuretic use (OR = 2.55, 95% CI: 1.09-5.95, p= 0.031) ), and body mass index (>= 25 vs <25) (OR = 1.94, 95% CI: 1.05-3.63), p= 0.034) was found to be predictive. Tamoxifen (OR = 4.71, 95% CI: 1.77-12.56, p= 0.002), hypertension (OR = 3.48, 95% CI: 1.27-9.52, p= 0.015), and age (OR = 2.35, 95% CI: 1.10-5.02, p= 0.027) remained independent predictors for incontinence in multivariate analyses.ConclusionWe found that tamoxifen had increased the risk of urinary incontinence compared to aromatase inhibitors in patients receiving hormone therapy for breast cancer. In addition, we showed that age and hypertension were also independent predictors for UI. In the context of quality of life, we recommend close follow-up of these patients, as drug adherence may be affected in the event of urinary incontinence.
dc.identifier.doi10.1007/s00520-023-07791-7
dc.identifier.issn0941-4355
dc.identifier.issn1433-7339
dc.identifier.issue6en_US
dc.identifier.pmid37162602
dc.identifier.scopus2-s2.0-85158852904
dc.identifier.scopusqualityQ2
dc.identifier.urihttps://doi.org/10.1007/s00520-023-07791-7
dc.identifier.urihttps://hdl.handle.net/20.500.11776/14206
dc.identifier.volume31
dc.identifier.wosWOS:000985786700002
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer
dc.relation.ispartofSupportive Care in Cancer
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectUrinary Incontinence
dc.subjectEarly breast cancer
dc.subjectAdjuvant hormone therapy
dc.subjectTamoxifen
dc.subjectAromatase inhibitor
dc.subjectICIQ-UI SF
dc.titleTamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu